Reading Time: 5 minutes"New drug reduces risk of death by 50%"

You may have seen this type of headline in news articles reporting on the outcome of clinical trials. Reading this headline can lead people to believe a potential drug is highly beneficial and has a real impact. However, it is important to delve a little deeper into the meaning of ‘risk of death’, the raw data behind it, and how it should be considered alongside other outcome measures of a trial to fully determine how effective a drug might be.

Read More

Reading Time: 5 minutesHi, my name is Avril Mc Tague. I am undertaking a Ph.D. at Trinity College, Dublin, Ireland as part of the Multidisciplinary Innovation and Research Advancing Neurological care in a Digital Age (MIRANDA) doctoral award programme. This is funded by the Health Research Board in Ireland. I was one of five symposium communication ambassadors at last year’s international symposium.

Read More
A graphic showing some of the photos of the ALS/FTD Plenary Speakers

Reading Time: 5 minutesEvery year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme. To give you a teaser of what is to come, we are taking a closer look at the plenary speakers in the ALS-FTD sessions at the Symposium. In this blog, we explore the topics they will be presenting and find out a little more about the speakers.

Read More